Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.
Caregivers of people with Duchenne muscular dystrophy may play an important role in the prevention and management of fat ...
BOSTON - Entrada Therapeutics , Inc. (NASDAQ:TRDA) received authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial for its ...
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...
It was the type of upsetting yet commonplace problem most parents face from time to time. Early last month, the Taylor family were on their way home from a meal out when Trey, 11, began feeling sick.
Barbara Goodfriend, 83, opted for medical aid in dying after being diagnosed with ALS. The New Jersey widow ended her life in ...
PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
The announcement was made at Arab Health 2025 where Sidra Medicine will highlight its international patient service programmes ...
Learn more about whether Avidity Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback